A novel solid formulation of a rivaroxaban eutectic using a hot …
The current work aims to enhance the solubility, dissolution rate and stability of the poorly water-soluble drug rivaroxaban (RXB) by preparing an amorphous solid dispersion (ASD) of its …
Modified rivaroxaban microparticles for solid state properties ...
2019年2月15日 · To tailor the solid state properties of rivaroxaban (RXB), microparticles were prepared using an anti-solvent precipitation technique. A mixture of hydroxypropyl …
A review on: analysis of the first oral, direct factor Xa inhibitor ...
2020年12月1日 · The presented review with 74 references covers most of the methods described for the analysis of Rivaroxaban (RXB); the first and selective oral direct inhibitor of activated …
(PDF) Preparation And Characterization Of Rivaroxaban …
2018年12月1日 · The objectives of this study were to develop rivaroxaban (RXB) nanocrystals by combination of wet ball milling and high-pressure homogenization, and to increase the …
Novel rivaroxaban-loaded poly(lactic-co-glycolic acid ... - PubMed
2021年3月26日 · Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile. However, RXB has shown adverse effects, mainly due to pharmacokinetic …
Rivaroxaban-loaded SLNs with treatment potential of deep vein ...
Objectives: Rivaroxaban (RXB), a novel Xa inhibitor having groundbreaking therapeutic potential. However, this drug is associated with few limitations, including its pharmacokinetics related …
(PDF) Enhanced Biopharmaceutical Performance of Rivaroxaban through ...
2017年12月29日 · Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor Xa, given as monotherapy in the treatment of venous thromboembolism …
Enhanced Biopharmaceutical Performance of Rivaroxaban through …
2017年12月29日 · Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor Xa, given as monotherapy in the treatment of venous thromboembolism …
The Development and Optimization of Hot-Melt ... - Pharma …
Rivaroxaban (RXB), a novel oral anticoagulant that directly inhibits factor Xa, is a poorly soluble drug belonging to Biopharmaceutics Classification System (BCS) class II.
Enhanced Oral Bioavailability of Rivaroxaban-Loaded ... - PubMed
2023年8月7日 · This study aimed to develop microspheres using water-soluble carriers and surfactants to improve the solubility, dissolution, and oral bioavailability of rivaroxaban (RXB). …